George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Gnanasakthy A, Russo J, Gnanasakthy K, Harris N, Castro C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp Clin Trials. 2022 Sep;120:106860. doi: 10.1016/j.cct.2022.106860
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Ling W, Nadipelli VR, Ronquest N, Albright VA, Aldridge AP, Learned SM, Mehra V, Heidbreder C. Remission from chronic opioid use-studying environmental and socio-economic factors on recovery (RECOVER): study design and participant characteristics. Contemp Clin Trials. 2019 Jan;76:93-103. doi: 10.1016/j.cct.2018.11.015
Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials. 2015 Apr 18;43:1-9. doi: 10.1016/j.cct.2015.04.004
Gnanasakthy A, DeMuro C, Boulton C. Integration of patient-reported outcomes in multiregional confirmatory clinical trials. Contemp Clin Trials. 2013 May 1;35(1):62-9.
Hareendran A, Gnanasakthy A, Winnette RM, Revicki D. Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012 Jan;33(1):23-8.
Stull DE, Wiklund I, Gale R, Capkun-Niggli G, Houghton K, Jones P. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials. 2011 Nov 1;32(6):818-28.